Shanghai Cingular Biotech

Cingular Biotech is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative therapies for chronic liver diseases, with a primary focus on Chronic Hepatitis B (CHB). The company leverages its proprietary GalNAc-conjugated siRNA platform to develop highly targeted treatments aimed at achieving a functional cure for HBV. Its lead candidate, XQ-001, is a siRNA therapeutic designed to silence viral gene expression and reduce HBsAg levels, currently in Phase 2 clinical trials. Cingular Biotech's pipeline also includes small molecule immunomodulators like TLR8 agonists to stimulate the host immune response. The company is backed by prominent venture capital firms such as Matrix Partners China and Source Code Capital. Cingular Biotech aims to address significant unmet medical needs in the global hepatology market through precision medicine and advanced RNA interference technologies.